Maze Therapeutics, Inc. (MAZE) P/E Ratio History
Deep ValueTrading at -7.9x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2025–2025
Loading P/E history...
P/E Ratio Analysis
As of June 12, 2026, Maze Therapeutics, Inc. (MAZE) trades at a price-to-earnings ratio of -7.9x, with a stock price of $24.09 and trailing twelve-month earnings per share of $-2.27.
The current P/E is 105% below its 5-year average of 172.0x. Over the past five years, MAZE's P/E has ranged from a low of 172.0x to a high of 172.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.1x, MAZE trades at a 134% discount to its sector peers. The sector includes 235 companies with P/E ratios ranging from 0.0x to 187.5x.
Relative to the broader market, MAZE trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MAZE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MAZE Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MAZE P/E vs Peers
Metabolic and Obesity Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 66.9 | 1.89Best | -10% | |
| $39B | 124.2 | - | +207% | |
| $9B | 47.0 | - | +128% | |
| $6B | 9.6Lowest | - | +264%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MAZE Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Mar 31 2025 | $11.01 | $0.06 | 172.0x | +0% |
Average P/E for displayed period: 172.0x
What if you invested $1,000 in MAZE back in 2025?
Total return with dividends reinvested · 1+ years of data
Calculate ReturnsHow much would $100/month in MAZE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs MAZE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationMAZE vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowMAZE — Frequently Asked Questions
Quick answers to the most common questions about buying MAZE stock.
What is MAZE's P/E ratio?
Maze Therapeutics, Inc. (MAZE) trailing twelve-month P/E ratio is -7.9x, based on TTM diluted EPS of $-2.27. The 5-year average P/E is 172.0x and the historical range spans 172.0x to 172.0x.
Is MAZE stock overvalued or undervalued?
MAZE trades at -7.9x P/E, below its 5-year average of 172.0x. At the 0th percentile of its historical range (172.0x–172.0x), the stock is priced at a discount to its own history.
Is MAZE stock expensive?
No, MAZE is not expensive on a historical basis. The current P/E of -7.9x is below the 5-year average of 172.0x and sits at the 0th percentile of its valuation range.
What is MAZE's historical P/E range?
Over the past 5 years, MAZE's P/E ratio has ranged from 172.0x to 172.0x, with a median of 172.0x and an average of 172.0x. The current P/E of -7.9x places the stock at the 0th percentile of this range. Full historical data spans 2025–2025.
How does MAZE's P/E compare to the S&P 500?
MAZE trades at -7.9x P/E versus the S&P 500 median of 24.9x. The 132% discount to the market suggests lower growth expectations or perceived higher risk.
How does MAZE's valuation compare to Healthcare peers?
Maze Therapeutics, Inc. P/E of -7.9x compares to the Healthcare sector median of 23.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MAZE's PEG ratio?
MAZE PEG ratio is N/A, based on a P/E of -7.9x and EPS growth of -4020.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MAZE's earnings yield?
MAZE earnings yield is N/A, the inverse of its -7.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.